<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335465">
  <stage>Registered</stage>
  <submitdate>11/05/2010</submitdate>
  <approvaldate>14/05/2010</approvaldate>
  <actrnumber>ACTRN12610000392066</actrnumber>
  <trial_identification>
    <studytitle>Replenishment of Vitamin D in Hip fractured Patients (REVITAHIP) Trial</studytitle>
    <scientifictitle>The effects of a high-dose oral vitamin D loading dose compared with placebo with maintenance oral vitamin D and calcium on correction of hypovitaminosis D, lower extremity function (gait velocity), falls and fractures among older people after hip fracture surgery</scientifictitle>
    <utrn>None</utrn>
    <trialacronym>REVITAHIP</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hip Fracture</healthcondition>
    <healthcondition>Hypovitaminosis D</healthcondition>
    <healthcondition>Rehabilitation</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Physical Medicine / Rehabilitation</conditioncode1>
      <conditioncode2>Other physical medicine / rehabilitation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>After surgical fixation and deemed medically stable, participants will be randomly allocated to an intervention group or placebo-control group. For the intervention group, participants will receive an initial oral 250,000IU (5 x 50,000IU) vitamin D3 tablets within 7 days following surgery. Both groups will receive oral maintenance vitamin D3 and calcium (800IU vitamin D3, 1000mg calcium daily) for 26 weeks and will follow the usual hip fracture rehabilitation pathway.</interventions>
    <comparator>Participants in the placebo group will receive a one-off dose of 5 x microcelllulose pills initially followed by oral maintenance vitamin D and calcium (800IU vitamin D3, 1000mg calcium).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>2.4m gait velocity</outcome>
      <timepoint>Baseline, 4 weeks and 26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum 25-hydroxyvitamin D levels via the DiaSoryn assay</outcome>
      <timepoint>Baseline, 2, 4 and 26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Falls and fractures (incidence assessed through telephone and face-to-face interviews)</outcome>
      <timepoint>Baseline, 2, 4, 12 and 26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life measured by EuroQoL (EQ-5D)</outcome>
      <timepoint>Baseline, 2, 4, 12 and 26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adherence to oral maintenance calcium-vitamin D (percentage with 80% adherence), incidence assessed through telephone and face-to-face interviews)</outcome>
      <timepoint>Baseline, 2, 4, 12 and 26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grip strength using a portable dynamometer (JAMAR hydraulic Hand Dynamometer manufactured by Sammons Prestons)</outcome>
      <timepoint>Baseline, 2, 4 and 26 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Adults (aged 65 or over) presenting with a hip fracture requiring surgical treatment 2. Able to provide informed consent, either directly or via the person responsible 3. Willingness to participate in and comply with the study 4. Deemed suitable by treating medical team for consent 5. Able to take loading dose by 7 days after operation</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Unable to read, speak or write English language (and interpreter not available) 2. Bed-bound prior to fracture, or life expectancy deemed less than 1 month (by the treating clinical staff) 3. Hypercalcaemia (serum calcium, &gt;2.65mmol/L). 4. History of renal stones 5. Thyrotoxicosis 6. Pagets disease 7. Malignancy (except skin cancer) and associated pathological fractures 8. Significant renal impairment (serum creatinine, &gt;0.15mmol/L) 9. Liver disease (alanine aminotransferase or aspartate aminotransferase level &gt;2 times the upper limit of the normal range); 10. Existing treatment with calcitriol or vitamin D2 &gt; than 1000IU daily.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After completion of the baseline assessment, participants will be formally entered into the study and randomised to intervention or control groups. It will be performed centrally by an investigator not involved in recruitment or assessments. The allocation will be concealed by the study staff ringing a central telephone number to be notified to which group the participant has been randomised.</concealment>
    <sequence>Randomisation will occur using a computer-generated random number schedule with variable block sizes.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>None</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2250</postcode>
    <postcode>2200</postcode>
    <postcode>2065</postcode>
    <postcode>2103</postcode>
    <postcode>2077</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Northern Sydney Central Coast Area Health Service, Gosford Hospital</primarysponsorname>
    <primarysponsoraddress>Department of Geriatric Medicine, 
PO Box 361, 
Gosford, 
New South Wales, 2250</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Australia</fundingname>
      <fundingaddress>54 Waterloo Road
North Ryde NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Australasian College of Physicians (Foundation Scholarship)</fundingname>
      <fundingaddress>Macquarie Street, Sydney</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Central Coast Area Health Service (Research Grant)</fundingname>
      <fundingaddress>Gosford Hospital, Holden Street, Gosford</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Rehabilitation Studies Unit, University of Sydney</othercollaboratorname>
      <othercollaboratoraddress>Northern clinical School - Sydney Medical School
The University of Sydney
PO Box 6
RYDE NSW 1680</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>School of Physiology, Bosch Institute, University of Sydney</othercollaboratorname>
      <othercollaboratoraddress>F13 - Anderson Stuart Building
The University of Sydney
NSW 2006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The REVITAHIP trial is a multicentre randomized-controlled trial examining the effects of early high-dose vitamin D replacement compared to placebo in improving mobility and reducing disability in older people following a hip fracture</summary>
    <trialwebsite>None</trialwebsite>
    <publication>Mak JCS, Stuart-Harris J, Cameron ID, Mason RS. Oral Vitamin D Replacement Following Hip Fracture: A Comparative Review. Journal of the American Geriatrics Society 2010; 58: 382417. 

Mak JCS, Cameron ID, Mason RS. REVITAHIP Protocol. Oral Presentation at the World Congress of Internal Medicine, Melbourne, Australia (20-25th March 2010).</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney &amp; Central Coast Health Research Office (HARBOUR)</ethicname>
      <ethicaddress>The Research Office
Level 2, Building 51
Royal North Shore Hospital
St Leonards NSW 2065</ethicaddress>
      <ethicapprovaldate>13/05/2010</ethicapprovaldate>
      <hrec>10/HARBR/14</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jenson Mak</name>
      <address>Department of Geriatric Medicine, 
Northern Sydney Central Coast Area Health Service,
Gosford Hospital
PO Box 361
Gosford, NSW, 2250</address>
      <phone>+612 4320 3141</phone>
      <fax>+612 4320 2986</fax>
      <email>jmak@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janine Tritton</name>
      <address>Department of Geriatric Medicine, 
Northern Sydney Central Coast Area Health Service,
Gosford Hospital
PO Box 361
Gosford, NSW, 2250</address>
      <phone>+612 4320 3141</phone>
      <fax>+612 4320 2986</fax>
      <email>jtritton@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janine Tritton</name>
      <address>Department of Geriatric Medicine, 
Northern Sydney Central Coast Area Health Service,
Gosford Hospital
PO Box 361
Gosford, NSW, 2250</address>
      <phone>+612 4320 3141</phone>
      <fax>+612 4320 2986</fax>
      <email>jtritton@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>